## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($142.70)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZAâ€™s Clinical Profile**
- Source: Sahm | 20251203T042204 | Somewhat-Bullish | Relevance: 97%
- Neurocrine Biosciences saw a 5.1% increase after a peer-reviewed study reinforced the clinical profile of its FDA-approved drug, INGREZZA, for tardive dyskinesia. The review consolidates over a decade of research, highlighting INGREZZA's distinct pharmacologic and dosing characteristics compared to other treatments. This positive development could strengthen INGREZZA's market position, though the company still faces challenges related to payer access and reimbursement.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |
| 2025-11-11 | Morgan Stanley | $173 | $178 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |
| 2025-11-11 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.72M) |
| Sells | 5 ($2.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.6x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (2 raises, avg +13%). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.6 |
| Current P/E | 22.1 |
| YoY Growth | 32.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.9% to 1.7% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.91), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.70% (CS: 72) | Neutral |
| RSI_14 | 61.0 | Neutral |
| MACD Histogram | 0.91 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $151.96
- **Stop Loss:** $142.70 (6.1% risk)
- **Target:** $161.22 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $15,499.92
- **Portfolio %:** 15.50%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*